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A B S T R A C T
Methylenetetrahydrofolate reductase (MTHFR) polymorphism has been shown to be associated with the development
of diabetic nephropathy in many ethnic groups. In this study, we examined the correlation between MTHFR C677T poly-
morphism and microalbuminuria in patients with diabetes mellitus type 2 in Croatian patients. 85 patients with diabe-
tes mellitus type 2 were recruited. Patients were classified into two groups – with and without diabetic nephropathy ac-
cording to urinary albumin excretion rate in urine collected during 24 hours. The C677T genotype was determined by
real-time PCR analysis. The genotype frequencies were CC 36,5%, CT 42,3% and TT 21,2% in diabetic patients without
nephropathy versus CC 39,4%, CT 45,4% and TT 15,2% in those with nephropathy. There was no statistically significant
difference in allele distribution between patients with nephropathy and those without (p=0,788). Our study did not show
a correlation between mutations in the MTHFR gene and diabetic nephropathy in Croatian patients. Diabetic
nephropathy is influenced by multiple risk factors which can modify the importance of MTHFR polymorphism in its de-
velopment.
Key words: allele distribution, methylenetetrahydrofolate reductase mutations, type 2 diabetes mellitus, diabetic ne-
phropathy, genetic polymorphism, Croatia
Introduction
Diabetes mellitus is the most frequent chronic meta-
bolic disease characterised by complications on blood ves-
sels, nerves and basal membranes of different tissues1.
The number of people with diabetes is constantly in-
creasing because of many reasons: aging of the popula-
tion, population growth, urbanization which includes
sedentary lifestyle and lack of physical activity and sig-
nificant increase of prevalence of obesity2. It is assumed
that the number of the diseased will increase from about
285 million adults in 2010 to 439 million adults in 20303.
The number of people with diabetes in Croatia is also in-
creasing, and diabetes is one of the leading causes of
death in Croatia4,5.
Diabetic nephropathy is a serious complication of dia-
betes mellitus and the leading cause of chronic renal dis-
ease and end stage renal failure6,7. The etiology of dia-
betic nephropathy is multifactorial and involves not only
chronic hyperglycaemia and arterial hypertension, but
also environmental factors and genetic susceptibility.
5,10-methylenetetrahydrofolate reductase (MTHFR)
is one of the key enzymes in the metabolism of homo-
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cysteine, where it catalyses homocysteine remethylation
to methionine. The thermolabile form of this enzyme
was discovered two decades ago8. The autosomal reces-
sive point mutation C677T in the MTHFR gene leads to a
valine-to-alanine substitution at amino acid 226. The re-
sult of this mutation is decreased activity and increased
thermolability of this enzyme9. There are three possible
genotypes in the case of the MTHFR C677T polymor-
phism. The CC genotype is refered to as »wild type«, the
CT genotype is described as »heterozygous« and the TT
genotype as the »homozygous variant«. Many studies
showed that patients who are homozygous for C677T
MTHFR mutation are predisposed to elevated homo-
cysteine levels in plasma compared with heterozygous or
wild type10.
The »homocysteine hypothesis of arteriosclerosis« was
first proposed in 1969 by McCully11. Since then, in addi-
tion to established risk factors, epidemiologic data and
many studies showed that elevated plasma homocysteine
concentration is an independent risk factor for vascular
disease12–20. Recent in vitro studies indicate that homo-
cysteine enhances the expression of VEGF (vascular en-
dothelial growth factor), which is a pro-angiogenic factor
with a known role in the pathogenesis of diabetic ne-
phropathy21,22. Based on this evidence, it can be consid-
ered that the polymorphism of C677T gene for MTHFR
as basis for hyperhomocystinaemia could be involved in
the development of diabetic nephropathy.
Many authors came to the conclusion that genetic
polymorphism of the MTHFR gene can have different in-
fluence on homocysteine metabolism and on the risk of
diabetic nephropathy in different ethnic groups. It was
assumed that homocysteine metabolism could be modi-
fied by genetic factors which can vary among different
populations7,21,24–26. On the other hand, some studies did
not prove such connection23,27.
The aim of this study is to determine the correlation
between MTHFR C677T polymorphism and microalbu-
minuria as an early sign of diabetic nephropathy in pa-
tients with diabetes mellitus type 2 in Croatian patients.
Subjects and Methods
Subjects
The subjects included in the study were men and
women who were ³18 years old and hospitalized in the
Medical Department during 2009. All included patients
were diagnosed with diabetes mellitus type 2 based on
1999 WHO and EASD & ESC classification and guide-
lines28,29. All of the patients on haemodialysis were ex-
cluded from the study in order to exclude the influence of
renal failure on homocysteine metabolism. The Hospital
Ethics Committee approved the study, and the informed
consent was obtained from all included participants. The
general data about all included subjects were recorded,
including age, gender, body weight, blood pressure. The
venous blood samples were collected for measurement of
glycosylated haemoglobin (HbA1c) and plasma venous
glucose level, and additional blood samples for MTHFR
C677T genotype analysis and analysis of total homo-
cysteine level were taken. Patients were classified into
two groups- with diabetic nephropathy or without it ac-
cording to urinary albumin excretion rate in urine col-
lected during 24 hours. Diabetic nephropathy was de-
fined as micro- or macroalbuminuria (³30 mg/24 h),
whereas normal albumin excretion rate was defined as
<30 mg/24 h30,31.
Determination of MTHFR genotype
The blood samples were taken from fasting subjects
and placed into vacutainer tubes containing EDTA. Leu-
kocyte DNA was isolated from whole-blood samples
(QIAamp DNA Blood Mini Kit). The C677T mutation in
the MTHFR gene was analyzed by polymerase chain re-
action (real-time PCR) of genomic DNA using the follow-
ing primer pairs: MTHFR-F: 5’-CCT CAA AGA AAA
GCT GCG TGA-3’and MTHFR-R: 5’-AAG CAC TTG
AAG GAG AAG GTG TC-3’. The analysis was conducted
on »Taqman 7300 Real Time PCR System«, Applied
Biosystems. According to the increase of the signal of the
defined essay, the SDS 1.3.1. Software 7300 Real Time
PCR System defined whether the samples were homozy-
gous for the wild type (C/C), heterozygous (C/T) or homo-
zygous for the mutation (T/T).
Homocysteine level measurement
The blood samples were taken into vacutainer tubes
containing EDTA during standard procedure. The homo-
cysteine level was determined by fluorescence polariza-
tion immunoassay technology (FPIA) on AxSYM homo-
cysteine machine, using AxSYM Homocysteine Reagent
Pack according to manufacturer’s instructions (Abbot).
According to the manufacturer’s package insert, hyper-
homocysteinaemia was defined as the homocysteine level
higher than 16.00 mmol/L for men, and higher than 20.44
mmol/L for women32.
Statistical analysis
The qualitative parameters are presented as absolute
numbers and percentages. The quantitative data are pre-
sented as median and range. The differences between
qualitative parameters were tested by c2 test, using Yates
correction in 2x2 tables. The differences in quantitative
data between two groups were tested by non-parametric
Mann-Whitney U test.
The statistical analysis was performed using Statis-
tica 6.0 software. In all tests, statistical significance was
taken at nominal p<0.05 for all comparisons.
Results
Eighty-five patients participated in the study, thereof
38 men (44.7%) and 47 women (55.3%). Out of 85 studied
patients, 33 (38.8 %) had evidence of microalbuminuria
(Table 1). The differences between qualitative parame-
ters were tested by c2 test, using Yates correction in 2x2
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tables. The differences in quantitative data between two
groups were tested by non-parametric Mann-Whitney U
test. There were no differences between patients with
and without diabetic nephropathy in terms of gender,
body weight, systolic blood pressure, plasma glucose level
and glycosylated haemoglobin. Differences between
those with and without nephropathy were noted for age
and homocysteine level.
In the analyzed group, 32 patients (37.65%) had the
C/C allele, whereas 37 (43.53%) were heterozygous (C/T)
and 16 (18.82%) were homozygous for the C677T muta-
tion (T/T). There was no statistically significant differ-
ence in allele distribution between patients with nephro-
pathy and those without (Table 2). Because of the depen-
dency of homocysteine level on the patient’s gender, the
statistical analysis of the correlation between the MTHFR
C677T mutation and the homocysteine level was per-
formed separately for males and for females32–36.
There was no statistically significant difference in the
homocysteine level considering the MTHFR genotype
(Table 3). In the group of males it is only noted that the
homocysteine level was somewhat higher in the group of
homozygotes (T/T), and the lowest in the group »wild
type« (C/C). This difference is notable, but not statisti-
cally significant.
Discussion and Conclusion
In this study, we analyzed the correlation of MTHFR
C677T gene polymorphism with diabetic nephropathy in
the population. MTHFR genotype and allele frequencies
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TABLE 1
CLINICAL CHARACTERISTICS OF PATIENTS CLASSIFIED INTO TWO GROUPS – WITH DIABETIC NEPHROPATHY AND WITHOUT IT
AER
p value
<30 mg/24h, N=52 ³30 mg/24h, N=33
Gender
– male
– female
22 (42.3%)
30 (57.7%)
16 (48.5%)
17 (51.5%)
0.738
Age (years) 65 (41–88) 71 (39–88) 0.022
Body weight (kg) 80 (52–157) 80 (65–150) 0.533
Blood pressure-systolic (mm Hg) 135 (90–220) 140 (110–170) 0.239
tlparHomocysteine (µmol/L) 12.5 (6.4–25.3) 15.2 (4.4–27.7) 0.023
Glucose level (mmol/L) 8.8 (4.3–19.8) 9.6 (3.8–24.3) 0.334
Glycosylated haemoglobin (%) 8.0 (6.1–12.2) 7.9 (6.1–14.7) 0.821
AER – albumin excretion rate
TABLE 2
METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) C677T GENOTYPES (NUMBER OF SUBJECTS AND PERCENTAGES)
IN PATIENTS WITH AND WITHOUT DIABETIC NEPHROPATHY
MTHFR C677T genotype
Albumin excretion rate
p value
<30 mg/24h, N=52 ³30 mg/24h, N=33
Homozygous (T/T) 11 (21.2%) 5 (15.2%) 0.788
Heterozygous (C/T) 22 (42.3%) 15 (45.4%) 0.788
»Wild type« (C/C) 19 (36.5%) 13 (39.4%) 0.788
MTHFR – methylenetetrahydrofolate reductase
TABLE 3
THE CORRELATION BETWEEN METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) C677T MUTATIONS AND THE
HOMOCYSTEINE LEVEL
Homocysteine level
(µmol/L) in:
MTHFR Mann-Whitney U test
T/T C/T C/C T/T vs. C/C C/T vs. C/C
All patients 13.7 (7.9–25.3) 13.1 (6.4–25.1) 13.4 (4.4–27.7) p=0.6777 p=0.937
Male 14.9 (9.5–25.3) 13.1 (6.4–25.1) 10.1 (4.4–27.7) p=0.0829 p=0.137
Female 13.1 (7.9–17.3) 13.4 (7.4–23.0) 15.2 (8.0–21.6) p=0.3798 p=0.535
MTHFR – methylenetetrahydrofolate reductase
were not different between type 2 diabetic patients with
and without nephropathy. This finding concurs with that
of Eroglu et al. who reported that the MTHFR gene
polymorphism is not associated with the development of
diabetic nephropathy in Turkish type 2 diabetic pa-
tients37. Similar results were obtained in Japanese popu-
lation23,38.
Unlike the above examples, many published research
papers pointed to the relationship between the MTHFR
gene polymorphism and the development of diabetic ne-
phropathy. The results of the research on Tunisian popu-
lation clearly showed that homozygosity for C677T and
hyperhomocysteinemia were associated with diabetic ne-
phropathy7. These findings are in agreement with obser-
vations in the Chinese population according to the re-
search of Sun and associates from 2004 and 2006 and
based on which authors concluded that MTHFR C677T
polymorphism could represent a genetic risk factor for
diabetic nephropathy in Chinese type 2 patients24. An-
other research in the Chinese Han population showed
similar results39. The confirmation of these results was
also obtained in Lebanese and Polish patients, but the re-
sults of another research on the Polish population speak
in favor of relationship between MTHFR polymorphism
and diabetic nephropathy only in male patients40–42. Fi-
nally, a meta-analysis of 15 available studies that ana-
lized the association between diabetic nephropathy and
MTHFR C677T showed heterogeneity between studies
and a marginal correlation between development of dia-
betic nephropathy and genetic polymorphism21.
It is evident that all above mentioned studies and re-
ports were conducted on different populations. Since ge-
netic factors can vary among different human groups,
ethnic variations of the genetic polymorphism of the
MTHFR gene could explain the variety of results in dif-
ferent populations.
From the results of our study it is obvious that pa-
tients in the group with diabetic nephropathy were sta-
tistically significantly older than in the normoalbumi-
nuric group. This result is not unexpected, since older
age is associated with reduced kidney function and crea-
tinine clearance, as well as with higher probability of lon-
ger duration of diabetes and its chronic complications.
The present study also shows that individuals with mi-
croalbuminuria had higher plasma homocysteine com-
pared with patients with normoalbuminuria. There is no
statistically significant difference in the homocysteine
level considering MTHFR polymorphism, in the whole
study population, or in separate groups of men and
women. Observing separately the group of men, a some-
what higher medium homocysteine level (14.9 mmol/L) is
evident in the group of homozygotes (T/T), and the low-
est in the group of »wild types« (10.1 mmol/L). This differ-
ence is probably not statistically confirmed due to a rela-
tively small number of patients. In the female part of the
population such a trend is not evident.
Some studies state that hyperhomocysteinaemia is
positively correlated with diabetic nephropathy. The stu-
dy conducted by Chico et al showed the results similar to
ours – patients with both types of diabetes and nephro-
pathy had higher plasma homocysteine levels than the
patients without nephropathy25. One Australian research
showed that patients with microalbuminuria had higher
levels of homocysteine than those with normoalbumi-
nuria43. Another study suggests significant correlation of
plasma homocysteine level with microalbuminuria, but
only in patients with diabetic nephropathy who had
C677T polymorphism44. In contrast, the findings pub-
lished by Soares et al did not find meaningful difference
between the subjects when homocysteine levels were as-
sessed according to the MTHFR genotype45. The differ-
ences between these results could be a consequence of
the diversity of laboratory methods, different analyzed
sample sizes, different nutritional status or could be ge-
netically determined.
In conclusion, our study did not show a correlation be-
tween MTHFR polymorphism and diabetic nephropathy
in Croatian patients. However, the possibility that
MTHFR polymorphism could be a risk factor for nephro-
pathy cannot be completely excluded because diabetic
nephropathy is influenced by multiple risk factors which
can modify the importance of MTHFR polymorphism in
its development. To detect that correlation it would be
necessary to conduct larger additional studies in patients
with diabetic nephropathy.
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POVEZANOST POLIMORFIZMA C677T GENA ZA METILENTETRAHIDROFOLAT REDUKTAZU I
DIJABETI^KE NEFROPATIJE U BOLESNIKA SA [E]ERNOM BOLESTI TIP 2 U HRVATSKOJ
S A @ E T A K
Polimorfizam gena za metilentetrahidrofolat reduktazu (MTHFR) je povezan s razvojem dijabeti~ke nefropatije u
mnogim etni~kim skupinama.U ovoj studiji istra`ivali smo povezanost izme|u polimorfizma C677T gena za MTHFR i
mikroalbuminurije u bolesnika sa {e}ernom bolesti tip 2 u hrvatskih bolesnika. Osamdeset pet bolesnika sa {e}ernom
bolesti je obra|ivano i svrstano u dvije skupine – sa dijabeti~kom nefropatijom i bez nje, ovisno o vrijednostima izlu~e-
nog albumina u 24-satnom urinu. Mutacija C677T gena za MTHFR odre|ena je metodom izolacije DNA i alel specifi~ne
lan~ane reakcije polimeraze (PCR). Raspodjela genotipova u skupini bolesnika s normoalbuminurijom bila je: CC
36,5%, CT 42,3% i TT 21,2%, dok je u skupini bolesnika sa mikroalbuminurijom bila: CC 39,4%, CT 45,4% i TT 15,2%.
Nije bilo statisti~ki zna~ajne razlike me|u grupama u distribuciji C677T genotipova (p=0,788). Na{e istra`ivanje nije
pokazalo povezanost izme|u mutacije gena za metilentetrahidrofolat reduktazu i dijabeti~ke nefropatije u hrvatskih
bolesnika. Mnogostruki ~imbenici mogu modificirati zna~ajnost utjecaja polimorfizmaMTHFR na nastanak dijabeti~ke
nefropatije.
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